CN115867645A - 修饰细胞的方法 - Google Patents

修饰细胞的方法 Download PDF

Info

Publication number
CN115867645A
CN115867645A CN202280005501.1A CN202280005501A CN115867645A CN 115867645 A CN115867645 A CN 115867645A CN 202280005501 A CN202280005501 A CN 202280005501A CN 115867645 A CN115867645 A CN 115867645A
Authority
CN
China
Prior art keywords
cell
less
nucleic acid
cells
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280005501.1A
Other languages
English (en)
Inventor
李林红
朱向阳
刘武青
于世钧
辛鹏程
王丽
张双双
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ceselqing Biotechnology Shanghai Co ltd
Original Assignee
Ceselqing Biotechnology Shanghai Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ceselqing Biotechnology Shanghai Co ltd filed Critical Ceselqing Biotechnology Shanghai Co ltd
Publication of CN115867645A publication Critical patent/CN115867645A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

一种修饰细胞的方法，所述方法包括：用转染组合物转染待修饰的细胞以使所述细胞包含和/或表达外源基因，所述转染组合物中含有包含所述外源基因的外源核酸分子，至少部分所述外源核酸分子获自宿主细胞；且在获自所述宿主细胞的所述外源核酸分子部分中，所述宿主细胞的基因组DNA的含量为约10％(w/w)以下。

Description

PCT国内申请，说明书已公开。

Claims (161)

  1. PCT国内申请，权利要求书已公开。
CN202280005501.1A 2021-05-18 2022-05-17 修饰细胞的方法 Pending CN115867645A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202110542564 2021-05-18
CN2021105425648 2021-05-18
CN202110541397 2021-05-18
CN2021105425845 2021-05-18
CN2021105413975 2021-05-18
CN202110542584 2021-05-18
PCT/CN2022/093334 WO2022242644A1 (zh) 2021-05-18 2022-05-17 修饰细胞的方法

Publications (1)

Publication Number Publication Date
CN115867645A true CN115867645A (zh) 2023-03-28

Family

ID=84141124

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280005501.1A Pending CN115867645A (zh) 2021-05-18 2022-05-17 修饰细胞的方法

Country Status (4)

Country Link
EP (1) EP4342983A1 (zh)
JP (1) JP2024519895A (zh)
CN (1) CN115867645A (zh)
WO (1) WO2022242644A1 (zh)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
EP1476180A4 (en) 2001-08-13 2005-04-20 Univ Southern California INTERLEUKIN-2 MUTANTS WITH REDUCED TOXICITY
CN100390282C (zh) 2001-12-04 2008-05-28 默克专利有限公司 具有调节的选择性的il-2融合蛋白
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
CA3055968A1 (en) 2005-10-18 2007-04-26 Duke University Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity
WO2008034473A1 (de) 2006-09-20 2008-03-27 Dge Dr.-Ing. Günther Engineering Gmbh Verfahren und vorrichtung zur trennung von methan und kohlendioxid aus biogas
US8906356B2 (en) 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
JP6463577B2 (ja) * 2013-05-14 2019-02-06 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 改変キメラ抗原受容体（ｃａｒ）ｔ細胞のヒト応用

Also Published As

Publication number Publication date
WO2022242644A1 (zh) 2022-11-24
EP4342983A1 (en) 2024-03-27
JP2024519895A (ja) 2024-05-21

Similar Documents

Publication Publication Date Title
CN107980059B (zh) 用于修饰基因组dna的方法和组合物
JP7209671B2 (ja) ゲノムｄｎａを改変するための方法および組成物
JP7292213B2 (ja) Ｃｒｉｓｐｒ／ｃｐｆ１を用いる、ｔ細胞における遺伝子編集のための組成物および方法
JP2022153470A (ja) ゲノムｄｎａを改変するための方法および組成物
AU2016291778B2 (en) Delivery methods and compositions for nuclease-mediated genome engineering
EP3057432B1 (en) Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
EP3500271A1 (en) Genome editing enhancers
WO2018071663A1 (en) Rna compositions for genome editing
WO2022113056A1 (en) Gene-edited natural killer cells
JP2024515936A (ja) Ｃａｓ酵素を用いたマルチプレックス編集
US20230158110A1 (en) Gene editing of monogenic disorders in human hematopoietic stem cells -- correction of x-linked hyper-igm syndrome (xhim)
WO2022242644A1 (zh) 修饰细胞的方法
Hajifathali et al. Novelty in improvement of CAR T cell-based immunotherapy with the aid of CRISPR system
KR20240043783A (ko) 유전자 변형 세포의 제조 방법
WO2024037461A1 (zh) 工程化免疫细胞及其制备方法
WO2023025208A1 (zh) 一种修饰细胞的方法
Liu et al. Manufacturing and delivering genome-editing proteins
WO2023233342A2 (en) Gene-edited natural killer cells
WO2022125671A1 (en) Delivery of molecules to cells using trogocytosis and engineered cells
CN116904514A (zh) 用双aav载体同步定点基因编辑制备car-t细胞的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40084392

Country of ref document: HK